HCTI HCTI
Company Profile ↓Company Overview
HCTI (HCTI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $13.89M (+18.8% YoY); net profit $-9.48M.
- Trailing 12 Months Year-on-year growth — revenue +18.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -15.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -15.02% |
| 1 Year: | 18.77% |
Stock Price Performance
| 1 Year: | -99.65% |
| 6 Months: | -92.53% |
| 3 Months: | -52.84% |
| 1 Month: | -39.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.15 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -15.0% CAGR over 5 years.
- Trading 99.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.36M | 7.95M | 10.05M | 8.08M | 11.06M | 11.59M | 11.95M | 9.84M | 8.53M | 7.78M | 4.11M | 2.98M | 2.41M | 3.70M | 3.56M | 3.49M | 3.14M | 9.86M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.38M | 3.06M | 2.87M | 2.69M | 7.46M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 1.07B | - | - | 329.00K | 494.00K | 618.00K | 448.00K | 2.39M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.73M | 1.85M | 3.21M | 4.87M | 5.89M |
| Operating Income | 191.31K | -716.00K | 469.00K | -1.77M | -1.97M | -1.43M | -2.25M | -3.21M | -1.59M | -1.52M | -1.71M | -1.38M | -1.17M | -1.40M | -1.36M | -2.59M | -4.43M | -3.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.27M | -1.35M | -1.81M | -3.77M | -5.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 413.00K | 21.00K | 32.00K | 100.00K | 85.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.70M | -1.37M | -1.91M | -4.50M | -6.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | 138.81K | -814.00K | 304.00K | -1.99M | -2.01M | -405.00K | -2.34M | -3.28M | -1.79M | -1.94M | -1.86M | -1.51M | -1.25M | -1.70M | -1.37M | -1.91M | -4.50M | -6.20M |
| Diluted EPS | 0.01 | -0.03 | 0.01 | -0.07 | -0.06 | -0.01 | - | -0.79 | -0.42 | -0.45 | -0.42 | -70.72 | -54.78 | -561.80 | -34.80 | -25.73 | - | -6.66 |
| R&D Expense | 550.17K | 757.00K | 813.00K | 2.20M | 1.07M | 646.00K | 1.47M | 539.00K | 102.00K | 54.00K | 127.00K | 207.00K | 175.00K | 144.00K | 55.00K | 59.00K | - | 85.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 31.34M | 35.27M | 45.89M | 33.20M | 11.70M | 13.89M |
| Gross Profit | - | - | - | 1.07B | 1.07B | 1.24B |
| Operating Income | 1.18M | -5.36M | -10.42M | -7.70M | -4.75M | -9.79M |
| Net Income | 2.35M | -5.95M | -9.61M | -8.69M | -5.97M | -9.48M |
| Diluted EPS | 0.08 | -0.20 | -2.63 | -2.08 | -16,909.30 | -152.30 |
| R&D Expense | 1.74M | 5.26M | 5.95M | 799.00K | 429.00K | 536.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 11.11M | 24.61M | 20.76M | 6.86M | 1.96M | 22.74M |
| Total Equity | 1.97M | 4.33M | 16.14M | 6.04M | -1.39M | -5.11M | 9.94M |
| Cash & Equivalents | 974.83K | 1.40M | 1.77M | 1.34M | 1.23M | 20.00K | 7.62M |
| Total Liabilities | - | 6.78M | 8.48M | 8.38M | 8.25M | 7.08M | - |
| Current Liabilities | - | 6.78M | 6.25M | 6.15M | 8.15M | 7.08M | 12.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -734.67K | -7.11M | -2.60M | -2.15M | -1.08M | -16.52M |
| Investing Cash Flow | -477.46K | -7.63M | -3.32M | -12.00K | - | -1.75M |
| Financing Cash Flow | 1.64M | 15.11M | 5.49M | 2.06M | -133.00K | 25.88M |
| Capital Expenditure | - | - | -40.00K | -12.00K | - | -6.00K |
| Free Cash Flow | - | - | -2.64M | -2.16M | - | -16.53M |
| Share Buybacks | - | - | 142.00K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 3,222.6% | 9,148.4% | 8,890.6% |
| Operating Margin % | 3.8% | -15.2% | -22.7% | -23.2% | -40.6% | -70.5% |
| Net Margin % | 7.5% | -16.9% | -20.9% | -26.2% | -51.0% | -68.2% |
| ROE % | 54.4% | -36.9% | -159.1% | 624.4% | 116.7% | -95.3% |
| ROCE % | 27.2% | -29.2% | -71.3% | 594.7% | 92.9% | -98.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCTI
Purpose Health CEO brings $175M scaling record to healthcare AI - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQaXE3M0F6Vkk2cFlOWTRnWDdLUTNMZXdUd19QbUZ0WHJpU09WMk53TnZWaUN4QlpaN0dtNVc1VzFfazllVjVVUDMwX0VjRk9JTFlfTTQwZFd6Qi1wRU5HZUlhQ2xhTHdfZWNGOHZXdkh5Mjk4bU1IODNDOWZyVUwtNGpwd2ZsZmFfOUJJV2…
Healthcare Triangle Expands Share Base, Strengthens Nasdaq Standing - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOS21vS1lwWGYzd2RSSTlyVHI3bHlHQTI5ZmRBblVKNDRjeU9fbVlyRUNucXZMZllJSVl3MFZQajBfd05kQTFlcGxJWlVFVkVWOUxxTFlIWHc3X2hNWXJmTmhNZWNfcG91OXk3aVNBc1NUVnYyU041Q0diYWVlV0huVF9LT1NsUWZUQk5SSl…
Healthcare Triangle Completes Share Issuances Relating to Legacy M&A Transactions, Strengthening Compliance With Nasdaq's New $5 Million Market Value Listing Standard - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMzZucHFFcmxwUTlUWTJIMnB2eWVKdFNxcXBERVRBRWNaVGRZMWU3UWF0MnRidDRaUmFOSEwwN2dOeTJHaVk0aVhWRnNrWXZrUDh0RFpqQXl4SkEzbEpZVmRlOFhINE1aaFRPT2I2OGNHU0dtbjF2VjNuNWl5Mk5tMlRnZTZhU2hrbGxHOC…
Healthcare Triangle, Inc. Actuals & Estimates (NASDAQ:HCTI) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQWm9Rc1ZDSUtZY3Q1MGc0bXFiM3RQZkdLajNwMGVQZlludHFDcjFCY0o1QXlIeENfN2NyOGFiLVhOS0dnUEQ2bFlPeXVnWEFNTTNSc1NMTVk4blVwWTRTdUs2bm9KeGR3M0JxcWl6OTJzdHhzMnp4Y0hNRDVJOGhTZ2hwcXhCQQ?oc=5" t…
HCTI Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1GeVF1Z0xmVDlhTmNmSEFZNnlQNlFHWEFMWG5RdXkwMTVicnkzSS1QeWJ6R1JEUkh4cjdiZUoyMHdVa1I1YThySEtscXZXbTJjbHNTSVRxUEFFNWkwRmc?oc=5" target="_blank">HCTI Should I Buy</a> <font c…
Healthcare Triangle completes share issuance for acquisitions - Investing.com
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQazVUamtBenYyTzVpTV90a0E2N1c2R01tRXNhNFBaWWE2U09JRmR0NnNfWXMyWWp6QnlxeVlVZWRhUGJvU0Q2dVpDbmYyNzM4QXV0VDVvTktrSVM0anVUeF8xNXVTeVRNTGtRbDJuaEE4WTJIV3dqRngxcnRET0NrQVQzREtraHJxYTNIV3…
HCTI — Frequently Asked Questions
What is the current share price of HCTI?
As of 2026-08-05 17:25 PDT, HCTI trades at $1.08 on NASDAQ/NYSE. Its 52-week range is $1.02 to $306.60.
What is the P/E ratio of HCTI?
HCTI trades at a trailing price-to-earnings (P/E) ratio of -0.01.
What is the return on equity (ROE) of HCTI?
HCTI has a return on equity (ROE) of -95.29%. Its return on capital employed (ROCE) is -98.44%.
Is HCTI a good stock to buy?
This page provides a data-driven analysis of HCTI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.